Results 31 to 40 of about 11,703 (213)

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Frontiers in Immunology, 2023
Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered to express transgenes, modulating the tumor microenvironment (TME), and ...
Lingjuan Chen, Mengsi Zuo, Qin Zhou, Yang Wang   +3 more
semanticscholar   +1 more source

Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways

Vaccines, 2020
Myxoma virus (MYXV) is the prototypic member of the Leporipoxvirus genus of the Poxviridae family of viruses. In nature, MYXV is highly restricted to leporids and causes a lethal disease called myxomatosis only in European rabbits (Oryctologous cuniculus)
Masmudur M. Rahman, Grant McFadden
doaj   +1 more source

Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook. [PDF]

Clin Transl Med
Oncolytic adenoviruses synergise with chemotherapy, radiotherapy and immunotherapy to enhance anti‐tumour efficacy. Chemotherapy and radiotherapy increase tumour susceptibility and antigen release through DNA damage, while immunotherapy restores T‐cell activity.
Iova V, Iova GM, Tudosie MS, Scrobota I, Smarandache CG.   +4 more
europepmc   +2 more sources

The Hitchhiker's Guide to Virotherapy

Oncotarget, 2012
In contrast to most other cancer therapies, early research with oncolytic viruses (OV) tended to use direct or intratumoural routes of administration, initially motivated by concerns that the major limitation of intravenous delivery would be immune attack against the viruses, whether by complement, cytokine or most critically neutralising antibodies ...
Donnelly, O, Vile, R, Pandha, H, Harrington, K, Melcher, A   +4 more
openaire   +5 more sources

Personalized virotherapy in cancer

Aging, 2015
After decades of intensive research, pancreatic adenocarcinoma (PDAC) remains a highly lethal disease with a median survival time that does not exceed 6.5 months [1]. Since more than 80% of patients present with advanced metastatic disease, systemic chemotherapy remains the only treatment.
Cafferata Eduardo G, Podhajcer, Osvaldo Luis   +1 more
openaire   +3 more sources

Oncolytic Virotherapy Trials—Letter [PDF]

Clinical Cancer Research, 2013
We would like to thank Prof. Harrington for his insightful commentary ([1][1]) regarding our article by Kanerva and colleagues ([2][2]). During 2007–2011, the Advanced Therapy Access Program (ATAP) provided a unique opportunity for patients to access a technology they would not otherwise have ...
Hemminki Akseli, Oksanen Minna, Hemminki Akseli, Oksanen Minna   +3 more
openaire   +2 more sources

Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration

Theranostics, 2023
Rationale: Immuno-virotherapy has emerged as a promising approach for cancer treatment, as it directly and cytotoxically eliminates tumors with systemic immune stimulation.
Yuzhi Liang, Bing Wang, Qingjing Chen, Xingyue Fu, Chenwei Jiang, Zhiwen Lin, Q. Zhuang, Yongyi Zeng, Xiaolong Liu, Da Zhang   +9 more
semanticscholar   +1 more source

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

Nature Communications, 2023
IDH1 mutations frequently occur early in human glioma. While IDH1 mutation has been shown to promote gliomagenesis via DNA and histone methylation, little is known regarding its regulation in antiviral immunity.
Xueqin Chen, Jun Liu, Yuqin Li, Yuequan Zeng, Fang Wang, Zexiong Cheng, Hao Duan, Guopeng Pan, Shangqi Yang, Yuling Chen, Qing Li, Xi Shen, Ying Li, Zixi Qin, Jiahong Chen, Youwei Huang, Xiangyu Wang, Yuli Lu, Minfeng Shu, Yubo Zhang, Guocai Wang, Kai Li, Xi Lin, Fan Xing, Haipeng Zhang   +24 more
semanticscholar   +1 more source

Oncolytic Viruses and the Immune System: The Dynamic Duo

Molecular Therapy: Methods & Clinical Development, 2020
Oncolytic viruses (OVs) constitute a new and promising immunotherapeutic approach toward cancer treatment. This therapy takes advantage of the natural propensity of most tumor cells to be infected by specific OVs.
Ana Lemos de Matos, Lina S. Franco, Grant McFadden   +2 more
doaj   +1 more source

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

Frontiers in Immunology, 2021
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them.
Victor Cervera-Carrascon, Victor Cervera-Carrascon, Dafne C. A. Quixabeira, Joao M. Santos, Joao M. Santos, Riikka Havunen, Riikka Havunen, Ioanna Milenova, Ioanna Milenova, Jan Verhoeff, Camilla Heiniö, Sadia Zafar, Juan J. Garcia-Vallejo, Victor W. van Beusechem, Tanja D. de Gruijl, Aino Kalervo, Suvi Sorsa, Anna Kanerva, Anna Kanerva, Akseli Hemminki, Akseli Hemminki, Akseli Hemminki   +21 more
doaj   +1 more source